Siguent Hycor (Hydrocortisone 1% Ophthalmic Ointment) is commonly used to provide localized relief from symptoms related to inflammatory or irritative states of the eye. Its therapeutic utility may assist with managing acute tissue reactions to support patient comfort during symptomatic episodes.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, generally helping to ease pronounced symptoms like ocular redness, swelling, and the general discomfort that may arise from these states. Key conditions where it is relevant include: allergic conjunctivitis, nonpurulent conjunctivitis, blepharitis (inflammation of the eyelid margins), recurrent marginal ulceration, and the inflammatory aspects of Herpes zoster ophthalmicus.

The core benefit provides support that helps ease the overall symptom burden, contributing to improved comfort during difficult episodes. As a general guide: “It is used in areas where short-term symptom management is appropriate and contributes to improved day-to-day comfort.”

Quick Fact: Relief for Inflammation
This ointment may assist with managing symptom clusters such as intense itching and visible swelling that interfere with daily comfort during acute flares of inflammation and ocular allergies.

Regulatory References

1. Australian NPS MedicineWise listing for Siguent Hycor

Siguent Hycor (Hydrocortisone 1% Ophthalmic Ointment) is subject to strict eligibility rules based on officially documented regulatory information.

Contraindicated Populations and Conditions

Use is absolutely contraindicated in patients with a known hypersensitivity to hydrocortisone or any component of the ointment. It must also not be used in the presence of acute viral eye infections (such as ocular herpes simplex, varicella, or vaccinia), ocular tuberculosis, fungal eye diseases, or untreated purulent infections of the eye, as the steroid component may worsen these conditions.

Restricted and Conditional Use

Population/Condition	Regulatory Status
Children	Not recommended for chronic use; consult a doctor due to higher risk of systemic toxicity.
Pregnancy	Conditional use (Category C); only if benefit outweighs risk. Prolonged, extensive use is discouraged.
Glaucoma/Cataracts	Requires caution; may exacerbate the condition or increase intraocular pressure.
Corneal Thinning Diseases	Requires caution; use carries a risk of eye perforation.

Eligibility is primarily established for Adults with specific non-purulent, inflammatory conditions. Patients with diabetes mellitus also require careful consideration due to the risk of steroid-induced eye pressure changes.

Interaction Patterns Documented in Regulatory Sources

Siguent Hycor contains hydrocortisone, a corticosteroid whose official interaction profile is defined by specific metabolic and pharmacodynamic interactions documented in regulatory materials. These interactions primarily reflect the effects associated with potential systemic exposure of the active ingredient.

Drug and Metabolic Interactions

Hydrocortisone is metabolized through the CYP3A4 enzyme system. Official documents indicate that potent CYP3A4 inhibitors—such as certain antifungals (e.g., ketoconazole) and antivirals (e.g., ritonavir)—may decrease hydrocortisone's hepatic clearance, a pharmacokinetic effect documented to potentially increase its concentration in the body. Conversely, CYP3A4 inducers (e.g., rifampicin, certain anticonvulsants) may accelerate clearance, potentially lowering systemic exposure.

Pharmacodynamic Interactions are also documented. Co-administration with potassium-depleting agents (e.g., certain diuretics) is associated with an officially documented increased risk of hypokalemia. Furthermore, the concurrent use of systemic corticosteroids with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is documented to increase the risk of gastrointestinal adverse reactions.

Ophthalmic and Substance Restrictions

For local ophthalmic use, the continued administration of the product may decrease the efficacy of anti-glaucoma agents due to a documented increase in intraocular pressure. Co-administration with anticholinergics (such as atropine and related compounds) may increase the likelihood of intraocular hypertension.

Regarding substances, Grapefruit Juice is explicitly listed in regulatory materials as a substance that inhibits the CYP3A4 enzyme, a metabolic interaction that may lead to increased hydrocortisone exposure. Official restrictions also state that live or live-attenuated vaccines are contraindicated if the corticosteroid is administered at a dose level considered immunosuppressive.

The action of Siguent Hycor is purely mechanistic, focusing on the suppression of cellular inflammation at the genetic level, thereby modulating the local immune response.

Activation of Intracellular Glucocorticoid Receptors

The drug's active component, Hydrocortisone, works as an agonist that binds to the Glucocorticoid Receptor (GR) inside target cells, a protein found primarily in the cytoplasm. This binding activates the receptor, allowing the complex to enter the nucleus and directly influence the cell's genetic code. This initial molecular step grants the medicine control over the fundamental cellular processes that drive inflammation.

---

Dual Control Over Inflammatory Gene Expression

Inside the nucleus, the activated receptor complex exerts its effect through dual actions: transrepression and transactivation. Transrepression suppresses the genes responsible for producing pro-inflammatory factors, such as the enzymes COX-2 and Phospholipase A2 (a key enzyme in the Arachidonic Acid cascade). Simultaneously, transactivation promotes the expression of anti-inflammatory proteins, which contributes to a reduction in the cell's ability to synthesize major inflammatory mediators like prostaglandins and leukotrienes.

---

Resulting Suppression of Local Physiological Response

This comprehensive molecular control leads directly to a suppression of the body's local defensive mechanism. By reducing the release of signaling chemicals and inhibiting the function of leukocytes (immune cells), the drug limits the key physiological events—vasodilation and increased vascular permeability—associated with altered vascular dynamics. This contributes to the modulation of the local tissue response.

Siguent Hycor 1% eye ointment, which contains the corticosteroid hydrocortisone acetate, is intended for topical application to the eye only and must not be swallowed. This medication is typically prescribed for inflammatory ocular conditions such as allergic conjunctivitis or swollen eyelids.

Administration Instructions

This medicine should be used exactly as directed by your healthcare professional, which usually involves application two to four times a day.

Step	Action
1. Preparation	Wash your hands thoroughly before and after applying the ointment.
2. Application	Tilt your head back slightly and gently pull the lower eyelid away from the eye to create a small pocket.
3. Dosing	Hold the tube with the tip as close to the eyelid as possible without making contact. Apply a small ribbon, typically about 1.25 cm (1/2 inch) long, of ointment into the lower eyelid pocket.
4. Post-Application	Gently close your eyes for one to two minutes to allow the medication to be absorbed. Do not rub or blink excessively. Immediately replace the cap on the tube.

Important Considerations

Avoid touching the tip of the tube to your eye or any other surface to prevent contamination of the sterile product. If you are using other eye medications, wait five to ten minutes after the other medication before applying the ointment. If a dose is missed, apply it as soon as possible, but skip the missed dose and return to your regular schedule if it is almost time for the next application. Do not use a double dose to compensate. You should consult your doctor if symptoms do not improve within a few days or if they worsen.

Research Evidence / Overview of Studies for Siguent Hycor

This overview summarizes the structure of the clinical research for Siguent Hycor (Ophthalmic Hydrocortisone Ointment), detailing what types of studies have been conducted, what was measured, and where evidence remains limited or uncertain. This information is based only on official and peer-reviewed scientific sources.

---

Evidence for Use in Acute Allergic Conjunctivitis

The most structured research base for ophthalmic hydrocortisone includes findings from Randomized Controlled Trials (RCTs). These short-term trials were conducted during periods of increased symptom activity and were evaluated in adult populations to compare the medicine against an inactive vehicle (placebo).

Research examined specific outcomes related to physical discomfort, such as itching, and outcomes linked to inflammatory or irritative states, such as changes in the degree of ocular redness. The findings describe patterns observed in the studies over the brief trial periods. This research contributes to understanding symptom patterns by documenting short-term changes in the populations studied.

---

Evidence for Other Acute Ocular Inflammations

For conditions categorized as other inflammatory states—including nonpurulent conjunctivitis, blepharitis, recurrent marginal ulceration, and the inflammatory component of Herpes zoster ophthalmicus—the research available is primarily derived from descriptive published literature, such as Case Reports and Case Series.

These studies explored conditions characterized by fluctuating or episodic manifestations. They monitored outcomes capturing phases of heightened symptom activity, documenting changes in visible signs of localized inflammation and the patient's reported symptomatic response. Because this evidence was observed in some studies that lacked a control group, the evidence quality varies across studies, and certainty remains low compared to controlled trials.

---

Research Gaps and Unanswered Questions

The primary limitation across the evidence base is the short duration of the available controlled trials, meaning long-term outcomes are not well characterized. Limited information is available regarding the consequences or patterns associated with repeated use. Furthermore, comparative evidence is lacking regarding how this ophthalmic ointment was evaluated against other active steroid or anti-inflammatory treatments. The data for certain groups remain insufficient, particularly for pediatric patients, as the main controlled trials research examined adults.

Key Studies & References

1. Risk Management Plan (RMP) for Hydrocortisone 1% Eye Ointment (Danish Medicines Agency)
2. Public Assessment Report Hydrocortisone acetate (The Netherlands Medicines Evaluation Board - CBG-MEB)

Common questions about Siguent Hycor (FAQ)

Q: What is Siguent Hycor eye ointment used for?

Siguent Hycor is an eye ointment that contains hydrocortisone acetate, a type of corticosteroid. It is used to treat inflammatory conditions of the eye that cause redness and swelling, such as:

• Allergic conjunctivitis
• Nonpurulent (non-pus producing) conjunctivitis or swollen eyelids
• Herpes zoster ophthalmicus (shingles affecting the eye)
• Recurrent marginal ulceration (recurring eye ulcers)

Q: What should I do if I miss a dose of Siguent Hycor?

If you miss a dose, apply the ointment as soon as you remember. However, if it is almost time for your next scheduled dose, you should skip the missed dose and continue with your regular dosing schedule. Do not use extra ointment to try to make up for the dose you missed.

Q: What are the possible side effects of Siguent Hycor?

The most common side effect is temporary blurred vision, which often occurs immediately after applying the eye ointment.

Less common or rare side effects may include:

• Burning, stinging, redness, or watering of the eyes
• Thinning of the cornea (which can lead to decreased vision or watering of the eyes)
• Cataracts
• Glaucoma (increased pressure in the eye)

If you experience any concerning side effects or if your eye condition worsens, you should contact your doctor or pharmacist.

Q: Are there any reasons why I should not use Siguent Hycor?

Siguent Hycor should not be used if you have certain existing eye conditions, including:

• Acute herpes infection of the eye (herpes simplex)
• Vaccinia (a specific form of chickenpox), varicella, or other viral infections of the eye
• Ocular tuberculosis
• Fungal diseases of the eye
• Pus-producing infections of the eye

Additionally, you should not use this medicine if you are allergic to hydrocortisone or any other ingredients in the ointment.

Q: Can I wear contact lenses while using Siguent Hycor?

No, it is generally recommended that you do not wear contact lenses while using Siguent Hycor eye ointment, as this may increase the risk of infection. You should talk to your doctor about when it is safe to resume wearing contact lenses. If you usually wear contact lenses, be sure to mention this to your doctor.

Siguent Hycor eye ointment must be stored below 25°C (77°F). It's crucial to keep the medicine in a secure location, such as a locked cupboard, out of the reach and sight of children. Do not store the ointment in the bathroom, near a sink, or leave it in a car or on windowsills, as this can expose it to excessive heat or moisture.

After you first open the tube, any remaining ointment should be discarded after 4 weeks. Using it past this point may pose a contamination risk. Additionally, do not use the product past the expiry date printed on the packaging, as its effectiveness may be compromised.

Action	Instruction
Storage Temperature	Below 25°C (77°F)
Post-Opening Shelf Life	Discard after 4 weeks

For proper disposal of expired or unused Siguent Hycor, do not throw it in household trash or flush it down the toilet. Consult your pharmacist or a local waste disposal company for guidance on medicine take-back programs or safe chemical waste disposal methods in your area.